FDA approves new pain pill Journavx, a non-opioid alternative to treat acute pain. Despite modest effectiveness, it shows promise in pain management.

Therapeutic breakthroughs in neuromodulation merge wearable technologies, deep brain implants, and tailored stimulations ...

The FDA approved Vertex Pharmaceuticals' Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, ...

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigin ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...

(Reuters) -The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals (NASDAQ: VRTX )' drug to treat acute ...